Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
68Ga-FAPI-46
Istituto Gentili S.r.l.
oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT
1 trial -
68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)
Istituto Gentili S.r.l.
Solid tumors
1 trial -
68Ga-FAPI-46, Sonelokimab
MoonLake Immunotherapeutics
psoriatic arthritis, axial spondyloarthritis
1 trial -
68Ga-G21
The First People's Hospital of Lianyungang
Prostate Cancer (Adenocarcinoma)
1 trial -
68Ga-NY104 PET/CT
The First People's Hospital of Lianyungang
Clear Cell Renal Cell Carcinoma
1 trial -
68Ga-NY104 PET/CT
Peking University Third Hospital
Clear Cell Renal Cell Carcinoma
1 trial -
75 mg LX4211
LEXICON PHARMACEUTICALS, INC.
Type 2 Diabetes Mellitus
1 trial -
851B
Takeda
Papillomavirus Infections
2 trials -
89Zr-Bevacizumab
Disc Medicine
NF2-related schwannomatosis
1 trial -
89Zr-Trastuzumab_IJB, Herceptin 150 mg powder for concentrate for solution for infusion, TRASTUZUMAB EMTANSINE
The George Institute
advanced/metastatic HER2-positive breast carcinoma
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Carcinoma
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Pancreatic Adenocarcinoma
1 trial -
91-day Levonorgestrel Oral Contraceptive
Teva Pharma GmbH
Bone Mineral Density
1 trial -
91-day Levonorgestrel Oral Contraceptive
Teva Pharma GmbH
Migraine
1 trial -
91-day Levonorgestrel Oral Contraceptive
Teva Pharma GmbH
Hemostasis
1 trial -
A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Advanced or metastatic squamous cell carcinoma of the esophagus
1 trial -
A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extensionβassessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic Ξ²-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy
Sanofi-aventis Healthcare Pty Ltd
Type 1 diabetes mellitus
1 trial -
A Clinical Trial for Patients with Advanced Cancers
Corbus Pharmaceuticals Holdings
Advanced Solid tumour
1 trial -
A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)
Merck Sharp and Dohme
Cancer β Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)
1 trial -
A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)
GlaxoSmithKline
Liver Diseases, Alcoholic
1 trial -
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
Ningbo Cancer Hospital
Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.
1 trial -
A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimerβs Disease.
GlaxoSmithKline
Alzheimer's Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources